News >

NICE Approves Frontline Pembrolizumab Regimen for Squamous NSCLC

Jason M. Broderick @jasoncology
Published: Thursday, Aug 08, 2019

Meindert Boysen

Meindert Boysen

The UK’s National Institute for Health and Care Excellence has authorized the use of pembrolizumab (Keytruda) in combination with carboplatin and either paclitaxel or nab-paclitaxel (Abraxane) for the treatment of patients with metastatic squamous non–small cell lung cancer (NSCLC).

The pembrolizumab combination is now available through the Cancer Drugs Fund to National Health Service patients in England.

“The committee heard from the patient experts that people with squamous non–small cell lung cancer often have a poor quality of life, and that treatments that have the potential to extend life would be of great importance,” Meindert Boysen, director of the NICE Centre for Health Technology Evaluation, said in a press release.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication
x